21 results about "Gamma delta T cell" patented technology

The application discloses a preparation method of CCR2+ gamma delta T cells with anti-tumor activity and migration ability, and belongs to the technical field of cells; the method comprises the following steps: step (1), PBMC of peripheral blood of a healthy person is extracted, inoculated into complete culture medium, and added with zoledronic acid, IL-15 and metformin, and then is cultured in a T25 culture bottle; step (2), complete culture medium is supplemented, the cell concentration is adjusted, and then the cells are transferred into a T75 culture bottle for culture; step (3), complete culture medium is supplemented, the cell concentration is adjusted, glucocorticoid and nicotinamide are added, and then the cells are transferred into a T150 culture bottle for culture; step (4), cells are collected at D6, rinsed with normal saline, resuspended with complete culture medium, the cell concentration is adjusted, and then the cells are inoculated into a T300 culture bottle for culture; and step (5), complete culture medium is supplemented every two days from D8 to D16, the cell concentration is maintained, and then the cells are harvested at D16 to obtain CCR2+ gamma delta T cells.

The present disclosure provides, among other things, a method of isolating and expanding gamma delta (γδ) T cells, wherein the method comprises: (a) isolating non-hematopoeitic tissue by biopsy or explant, and (b) culturing the isolated non-hematopoeitic tissue in the absence of a three-dimensional scaffold or grid, thereby expanding and isolating gamma delta (γδ) T cells.

Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and / or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.

Compositions and methods for stimulating the proliferation and cytotoxicity of γδ T cells are described. Therapeutic compositions and methods using the expanded and stimulated γδ T cells are described.

The present invention relates to a method for producing gamma delta (γδ) T cells. The present invention also relates to the cells obtained by said method and said cells for their use as a medicament and in an immunotherapy, preferably in the treatment or prevention of a cancer.

The application belongs to the technical field of biotechnology, and particularly relates to a staged precise regulation in vitro expansion culture method of high-activity gamma delta T cells. In the synergistic activation stage, the complex activator containing zoledronic acid, IL-2, IL-15, IL-12 and IL-21 is used to significantly improve the early activation level of the gamma delta T cells; in the dynamic expansion stage, the concentration of metformin is adjusted step by step to support the continuous and efficient proliferation of the cells; in the gradient maturation stage, the combination system of N-acetyl cysteine, TWS119 and DL-alpha tocopheryl acetate is introduced to help maintain the functional activity and antioxidant state of the cells in the later culture stage. The gamma delta T cells with a purity higher than 90% and an expansion multiple more than 100 times can be obtained by using the method to culture for 10 days, and the cells exhibit significant killing activity to tumor cells, are suitable for the adoptive immunotherapy of tumor and infectious diseases, and have good clinical application prospects.

Compositions and methods disclosed herein can comprise a cell (e.g., gamma delta T cell) engineered to comprise a nucleic acid molecule that encodes an immunizing polypeptide, and the engineered cell can present one or more T cell epitopes from the immunizing polypeptide via HLA, thereby inducing activation of endogenous T cells in a subject (e.g., host or recipient of the engineered cell). The cells can further express a CAR, facilitating induction of (1) a direct immune response mediated by the CAR, and (2) induction of immune responses (e.g., anti-cancer) mediated by the subject's endogenous T cells, for example, against different target antigens or T cell epitopes than those targeted by the CAR. Such a cell can be described as a Dual-action Antigen-presenting CAR γδ T-cell (DACART). DACART can combine the strengths of CAR T-cell therapy with those of cancer vaccination.

The application provides a high-efficiency expansion culture method of umbilical cord blood gamma delta T cells and application thereof, and belongs to the technical field of biological medicine. Through a specific two-stage strategy of "initial induction culture + expansion culture", the application is simple in operation, stable in system, and high in success rate, effectively overcomes the defects of limited autologous blood source, unstable expansion and low cell activity in the prior art, and lays a foundation for large-scale preparation and allogeneic application of gamma delta T cells. The umbilical cord blood gamma delta T cells obtained by the method of the application are excellent in quantity, purity, activity and anti-tumor function, and have stronger tumor cell killing ability, and are especially suitable for adoptive immunotherapy. The application breaks through the technical bottleneck of the traditional culture system, provides a high-efficiency, stable and clinically convertible gamma delta T cell expansion scheme, and has important application prospect and market value.

The present disclosure relates to a field of immunotherapy. Particularly, the present disclosure provides methods for production of gamma delta T (γδ T) cells and the γδ T cells produced therefrom.

This invention relates to the expansion of non-haematopoietic tissue-resident γδ T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and / or interleukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident γδ T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident γδ T cells and uses thereof.

The present invention provides methods of expanding γδ T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded γδ T cells and methods of using the expanded γδ T cells (e.g., a part of an adoptive T cell therapy).

The present invention provides a method for producing a γδT cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an αβT cell.

The present invention provides a method for producing a γδT cell from an induced pluripotent stem cell, wherein the induced pluripotent stem cell is derived from a cell other than an αβT cell.

The present invention relates to a method for producing gamma delta (γδ) T cells. The present invention also relates to the cells obtained by said method and said cells for their use as a medicament and in an immunotherapy, preferably in the treatment or prevention of a cancer.

The present application relates to the field of cell biology, specifically will be by adding phosphoantigen (HMBPP), IL-2 and other factors, specific activation of gamma delta T cells, and Daudi lymphoma cell feeder layer co-culture, promote the expansion of gamma delta T cells, at the same time, promote the memory phenotype and survival of gamma delta T cells, and improve the cytotoxicity and function of gamma delta T cells. The method simultaneously induces peripheral blood mononuclear cells to become gamma delta T cells and activates gamma delta T cells, enhances immune signal transduction, and significantly improves the activation efficiency and expansion capacity. The results show that the proliferation of gamma delta T cells is 742.62 times in 14 days, which is significantly higher than that of conventional CIK culture; CD3 + cell ratio reaches 90.15%, which is better than 75.29% of CIK. Thus, a short cycle, high yield, and good purity gamma delta T cell preparation process is formed, which embodies the creativity of multi-factor synergy and feeder layer co-culture, and brings significant beneficial effects.

The present disclosure relates to polymeric compositions and methods for activating gamma delta T cells, specifically Vγ9Vδ2 T cells, in cancer immunotherapy. These compositions include a cell-targeting moiety and a polymer incorporating phosphoantigens (pAgs) for targeted delivery to tumor cells. The method involves administering an effective amount of these compositions to a subject, allowing controlled release of pAgs in the tumor microenvironment. This approach overcomes limitations of systemic pAg administration and can be used alone or with adoptive transfer of Vγ9Vδ2 T cells or PBMCs. The treatment may involve repeated administrations and is applicable to various cancer types. This disclosure also covers methods for synthesizing these compositions and their use in cancer treatment applications.

The application discloses a DMSO-free cell cryopreservation solution based on an injection-grade protection system, a use method, related products and application, and belongs to the technical field of immune cell storage. The technical problem to be solved is to provide a cell cryopreservation solution which does not use DMSO and animal-derived components and has higher cell survival rate and higher gamma delta T cell ratio after recovery. The technical solution points are as follows: the cell cryopreservation solution comprises the following components: a colloidal protection component, a cold stabilization component, an antioxidant component, an energy and basic osmotic balance component, an extracellular electrolyte homeostasis regulation component and a transmembrane osmotic pressure regulation component; the osmotic pressure of the cell cryopreservation solution is 280-380 mOsm / kg, the pH of the cell cryopreservation solution is 7.0-7.4; the cell cryopreservation solution does not contain DMSO, animal serum and animal-derived substances. The cell cryopreservation solution is suitable for the storage and transportation of gamma delta T cell treatment products, the storage of an immune cell bank, the cryopreservation of cell treatment before return and the like.

This invention relates to γδT cell culture technology, specifically a method and application for activating γδT cells using circulating tumor cells (CTCs) or their derivatives. The method includes obtaining donor-derived γδT cells; obtaining CTCs or their derivatives from cancer patients; and co-culturing the γδT cells with the CTCs or their derivatives in an in vitro co-culture system, thereby activating the γδT cells under the stimulation of the CTCs or their derivatives to obtain CTC-γδT cells. This invention utilizes patient-derived circulating tumor cells as the activation stimulus for γδT cells, enabling the resulting γδT cells to recognize tumor-associated antigens and personalized neoantigens, overcoming tumor heterogeneity and antigen escape problems.

The present application relates to the technical field of culture medium preparation, in particular to a factor kit for culturing gamma delta T cells, a culture medium and application thereof, comprising the following raw materials by weight: 30-50 parts of a composite cytokine core, 20-30 parts of a composite anti-aggregation stabilizer, and 10-20 parts of a composite metabolic regulator; the present application processes interleukin-2, significantly improves its stability and anti-aggregation performance through electrostatic self-assembly, emulsification cross-linking and freeze-drying protection reaction; interleukin-15 realizes long-acting slow release and activity maintenance through electrostatic shielding, multiple emulsion embedding and skeleton support reaction; transforming growth factor-beta effectively solves the problem of easy adsorption and inactivation through affinity protection, biomimetic embedding and molecular inclusion reaction; through the synergistic effect of the three modified factors, the half-life of the cytokine in the culture system is prolonged, the adding frequency is reduced, and the gamma delta T cells obtained through culture have higher expansion fold and tumor killing activity.

This invention provides a method for obtaining a population of Vγ4 T cells for T-cell immunotherapy against cancer. [Solution] An ex vivo method for modulating Vγ4T cells is provided, comprising administering an antibody or fragment thereof that specifically binds to the gamma variable 4 (Vγ4) chain of the γδT cell receptor (TCR) and does not bind to the gamma variable 2 (Vγ2) chain of the γδTCR to a cell population including Vγ4T cells.